2025-2026 Regular Session • New York Legislature
S00488
Legislative Summary
Enacts the manufacturer disclosure and transparency act requiring prescription drug manufacturers to notify the attorney general of arrangements between pharmaceutical manufacturers resulting in the delay of the introduction of generic medications.
Demographic Impact
Overall analysis of equity impact
80% Positive
High ConfidenceView detailed demographic breakdown ↓Unlock Full Demographic Insights
Go beyond the overall score.
Gain a deeper understanding of this bill's potential impact across diverse communities, including detailed breakdowns by category and subgroup. Access to this granular analysis helps ensure equitable outcomes.
Enable full analysis features for your organization.
Contact Sales to Learn MoreOr email us directly at sales@legiequity.us.
Bill History
1/8/2025
REFERRED TO CONSUMER PROTECTION
Senate
1/28/2025
1ST REPORT CAL.204
Senate
2/3/2025
2ND REPORT CAL.
Senate
2/4/2025
ADVANCED TO THIRD READING
Senate
2/25/2025
PASSED SENATE
Senate
2/25/2025
DELIVERED TO ASSEMBLY
Senate
2/25/2025
referred to consumer affairs and protection
Assembly
5/22/2025
RECALLED FROM ASSEMBLY
Senate
5/22/2025
returned to senate
Assembly
5/22/2025
VOTE RECONSIDERED - RESTORED TO THIRD READING
Senate
5/22/2025
AMENDED ON THIRD READING 488A
Senate
Roll Call Votes
Senate Floor Vote - Final Passage
2/25/2025
50
Yea
11
Nay
0
Not Voting
2
Absent
Result: PASSED
Senate Consumer Protection Committee Vote
1/28/2025
6
Yea
1
Nay
0
Not Voting
0
Absent
Result: PASSED
Status Information
Current Status
Engrossed(2/25/2025)
Chamber
Senate
